Retatrutide is an investigational peptide designed to activate GIP, GLP-1, and glucagon receptors simultaneously. Clinical trials have demonstrated substantial effects on body weight and metabolic measures, but it remains investigational rather than an approved medicine. Its long-term safety profile and appropriate clinical role continue to be evaluated in ongoing research.